Market Overview

UPDATE: Jefferies Upgraded Charles River Laboratories to Buy on Tailwinds

Related CRL
Charles River Beats on Q2 Earnings & Revenues, Outlook Upped
Valeant's Jublia Approved in the U.S. - Analyst Blog

Jefferies upgraded Charles River Laboratories (NYSE: CRL) from Hold to Buy and raised the price target from $41.00 to $50.00.

Jefferies commented, "We view CRL as the relative value Buy in CROs. Its business mix grows at a slower rate, but accelerating, R&D spending growth rebounds from its trough. Management is successfully broadening relationships to steepen the growth curve. We liken this to PRXL's aggressive move toward strategic deals in late-'09/'10, except that ED revenue converts much faster. Our survey shows ED spending normalizing, while pharma capacity declines."

Charles River Laboratories closed at $40.46 on Friday.

Latest Ratings for CRL

DateFirmActionFromTo
Aug 2014Deutsche BankMaintainsHold
Aug 2014JP MorganMaintainsOverweight
Aug 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (CRL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters